All In Biotech

Drug Trial Radar · NCT04882774

Telemonitoring to Treat Group 2 Pulmonary Hypertension

Telemonitoring to Treat Group 2 Pulmonary Hypertension: A Personalized Approach

Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 2023

Primary completion

Apr 2025

Study completion Apr 2027

Sponsor

Lead sponsor
Mardi Gomberg -Maitland MD, MScAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ohio State University; Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
First posted
May 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to decrease elevated pressure in the lungs of patients with pulmonary hypertension from left heart with elevated pulmonary vascular resistance by utilizing aggressive fluid management with ReDS Pro System and CardioMEMS device. Participants with persistently elevated pulmonary pressure at Week 16 will begin oral treprostinil in combination with the fluid management plan while those with improved pressures maintain their fluid management plan for an additional 16 weeks.

Conditions

  • Pulmonary Hypertension Due to Left Heart Disease

Interventions

  • Treprostinil DiolamineDrug

    Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with normal lung impedance as measured by the ReDS vest in Ohms at Week 16Time frame: 16 weeks
  2. Number of participants with normal total pulmonary resistance as measured by CardioMEMS in Woods Units at Week 16Time frame: 16 weeks
  3. Number of participants reaching normal lung impedance with oral treprostinil at Week 32Time frame: 16 weeks
  4. Number of participants reaching normal total pulmonary resistance with oral treprostinil at Week 32Time frame: 16 weeks
  5. Number of participants decreasing six-minute walk distance with oral treprostinil at Week 32Time frame: 16 weeks
  6. Number of participants maintaining normal lung impedance as measured by the ReDS vest at Week 32Time frame: 16 weeks
  7. Number of participants maintaining total pulmonary resistance as measured by CardioMEMS at Week 32Time frame: 16 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • George Washington University

    Washington D.C., District of Columbia

  • Ohio State University

    Columbus, Ohio

  • Allegheny Singer Research Institute

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.